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Abstract
The clinical spectrum following infection with Shiga toxin-producing Escherichia coli (STEC) is wide ranging and includes
hemorrhagic colitis and life-threatening hemolytic uremic syndrome (HUS). Severity of STEC illness depends on patients’ age
and strongly on the infecting strains’ virulence. Serogroup O157 is often assumed to be more virulent than others. Age-
adjusted population-based data supporting this view are lacking thus far. We conducted a large retrospective cohort
study among patients of community-acquired gastroenteritis or HUS diagnosed with STEC infection, reported in Germany
January 2004 through December 2011. Age-adjusted risks for reported hospitalization and death, as proxies for disease
severity, were estimated for STEC serogroups separately, and compared with STEC O157 (reference group) using Poisson
regression models with robust error estimation. A total of 8,400 case-patients were included in the analysis; for 2,454
(29%) and 30 (0.4%) hospitalization and death was reported, respectively. Highest risks for hospitalization, adjusted for age
and region of residence, were estimated for STEC O104 (68%; risk ratio [RR], 1.33; 95% confidence interval [CI], 1.19–1.45),
followed by STEC O157 (46%). Hospitalization risks for the most prevalent non-O157 serogroups (O26, O103, O91, O145,
O128, O111) were consistently and markedly lower than for O157, with the highest RR for O145 (0.54; 95% CI, 0.41–0.70) and
the lowest for O103 (0.27; 95% CI, 0.20–0.35). Mortality risk of O104 was similar to O157 (1.2% each), but the group of all
other non-O157 STEC had only 1/10 the risk (RR, 0.09; 95% CI, 0.02–0.32) compared to O157. The study provides
population-based and age-adjusted evidence for the exceptional high virulence of STEC O157 in relation to non-O157 STEC
other than O104. Timely diagnosis and surveillance of STEC infections should prioritize HUS-associated E. coli, of which STEC
O157 is the most important serogroup.
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Introduction
Shiga toxin-producing Escherichia coli (STEC) are a heteroge-
neous group of organisms [1–3] and the clinical spectrum caused
by gastrointestinal infection with STEC varies widely [4,5].
Besides asymptomatic infection it includes acute non-bloody
diarrheal illnesses, but also hemorrhagic colitis and the hemolytic
uremic syndrome (HUS), a life-threatening thrombotic microan-
giopathy leading to acute renal dysfunction approximately one
week after onset of diarrhea. STEC of serotype O157:H7 is the
leading cause of pediatric HUS [6,7]. Because of the pathogen’s
inability to ferment sorbitol within 24 hours, culture identification
of this serotype is easy, reliable and inexpensive [8].
Numerous other STEC serotypes exist [9] and many have been
isolated from humans [10–12]. In many regions, these ‘‘non-
O157’’ STEC are at least as commonly identified as STEC of
serogroup O157 (comprising H7 and, less frequently, H- serotypes)
in patients with acute community-acquired diarrhea [13–18].
However, diagnosis of sorbitol-fermenting non-O157 STEC is
complex and requires nonculture screening strategies because
selective and differential media are not available for their culture
[19]. The historically rooted distinction between (sorbitol-non-
fermenting) STEC O157 and (sorbitol-fermenting) non-O157
STEC is still widely upheld [19]. This is probably due to these
differences in diagnosis and the notion - supported by several
studies - that STEC O157, on average, is more virulent than many
if not all other STEC serogroups [20,21], and is particularly
outbreak-prone [22]. This notion, however, is not unequivocal
[23–25]. The discrepant diagnostic approaches for O157 and non-
O157 STEC and the frequency with which they are performed
[26,27] impede studies on serogroup-specific virulence or burden
of illness in many countries that primarily use selective and
differential media for identifying STEC O157. Inferences or
generalizations of recent epidemiological studies of STEC
infections are often hindered by convenience sampling [11,28]
or by drawing on a limited number of laboratories or a small
geographic area [14–17,20,21,29–32]. Furthermore, severity of
STEC illness likely depends on patients’ age, as indicated by the
observation that the median age of STEC O157 patients with
HUS is younger than those without HUS [33]. Yet, none of the
sparse population-based comparisons between STEC serogroups
has accounted analytically for the possible confounding effect of
patients’ age.
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In Germany, STEC diagnosis is based on detection of Shiga
toxins by immunoassays or their encoding genes by polymerase
chain reaction, allowing for serogroup-independent identification
of STEC. Subsequent culture isolation and serotyping is recom-
mended but not mandatory and rarely performed in clinical
laboratories. It is frequently performed by the German National
Reference Center for bacterial enteric pathogens. The objective of
our study was to quantify the age-adjusted risk of hospitalization
and death separately for STEC serogroups, including O104 that
caused a large outbreak in 2011 [34], and compare non-O157
serogroups with STEC O157 in Germany.
Methods
Data source
Data were extracted from Germany’s national reporting
database on infectious diseases, hosted by the Robert Koch
Institute (RKI), Germany’s federal level public health institute. In
Germany, both serogroup-independent detection of STEC in stool
and clinically diagnosed ‘‘enteropathic’’ (i.e., diarrhea-associated)
HUS are reportable entities. For every notified person in Germany
fulfilling the surveillance case definition (see below), a case report is
filed by the local health department and transmitted (without
name and address of the patient) electronically, via state health
departments, to the RKI. The surveillance case definition for
STEC gastroenteritis (without HUS) requires detection of Shiga
toxin or their encoding genes from stool culture or detection of
Shiga toxin genes from stool enrichment culture in a person with
symptoms compatible with STEC-gastroenteritis, i.e., at least one
of the following: diarrhea (three or more loose stools in a 24 hour
period), abdominal cramps or vomiting. The case definition also
includes persons with compatible clinical symptoms without
laboratory-confirmation if they are epidemiologically linked to a
laboratory-confirmed case (these cases represent ,2%). The
surveillance case-definition for HUS requires that two of the
following three criteria are marked on the case report: hemolytic
anemia, thrombocytopenia (platelet count #150,000/mm3), or
acute renal dysfunction, defined as either oliguria (,500 ml/
24 h), or proteinuria, or hematuria.
An electronic case-report includes, among other entities,
information on age, sex and county of residence, hospitalization,
and death of the patient. Health departments are asked to mark
the field for death if the infectious disease had contributed to the
death. An email is sent to the local health department with the
purpose of verifying such death notices and the assessment of a (co-
)causal contribution of the infectious disease. In addition, the case-
report includes the following dates: disease onset, diagnosis,
reporting and, where applicable, hospitalization and death.
Study Design
We conducted a retrospective cohort study among patients with
community-acquired gastroenteritis or HUS in whose stool STEC
was detected, reported in Germany from January 2004 through
December 2011 and for whom a report was transmitted to the
RKI according to the surveillance definition. For HUS cases,
evidence for an STEC infection could also be established by
detecting anti-lipopolysacharide IgM antibodies against E. coli
serogroups in blood.
We used two outcomes as a proxy for disease severity: reported
hospitalization and death. Covariates besides STEC serogroup
were cases’ age, sex, region of residence, and season of infection.
For descriptive analysis and for serogroup-specific analysis of
hospitalization risks, the serogroup variable had the following
categories: O157, O145, O128, O111, O104, O103, O91, O26
(the 8 most frequently reported O antigens), the group of all other
detected serogroups (‘‘other’’), and the group of all cases without
serogroup information (‘‘unknown’’). For a comparison of O157
with all ‘‘conventional’’ non-O157 STEC (i.e., all except O104),
we additionally conducted an analysis with a recoded serogroup
variable that combined all cases with a known serogroup, except
O157 and O104, into one category. This coding was also used for
analysis of serogroup-specific mortality risks. Age groups (,3
years, 3–9 years, 10–18 years, 19–40 years, 41–65 years, and .65
years) were generated based on nonlinear descriptive analysis
using locally weighted regression (LOWESS, [35]), biological
plausibility, and strata size. Information of cases’ county of
residence was aggregated to four German geographic regions of
residence (North, East, South, West). Seasonality of disease was
categorized into ‘‘spring’’ (calendar week [CW] 9–21), ‘‘summer’’
(CW 22–34), ‘‘fall’’ (CW 35–47), and ‘‘winter’’ (CW 48–8)
generated from cases’ reporting dates.
We excluded cases from all analyses if they had missing values in
covariates (age, sex, residence) or the binary outcome variable. As
it is impossible to assess risk of hospitalization in already
hospitalized patients, we also excluded those with potentially
hospital-acquired infection, i.e. if their date of admission to the
hospital preceded the date of symptom onset by at least two days
(the minimum incubation period for STEC O157). For hospital-
ized cases with missing date of symptom onset or hospitalization
(n = 931), we conducted a single logistic imputation procedure,
based on the relation between hospital-acquired STEC- infection
and covariates (STEC-serogroup, age, sex, region of residence,
and season of infection), to classify them as hospital-acquired or
not.
Statistical analysis
Statistical analyses were conducted using Stata/IC, version 12.1
(StataCorp LP, College Station, TX, USA). Univariable analysis
was conducted using Poisson regression with robust error variance
to estimate risk ratios (RR) and 95% confidence intervals (CI) [36].
Logistic regression models were used to select covariates for
adjusting the relationship of serogroups and hospitalization or
death, respectively. Age was forced into the model because of its
assumed independent effect on disease severity. A manual forward
selection strategy was used for possible inclusion of further
covariates. Selection was based on improvement of the logistic
regression model assessed by the Bayesian information criterion
(BIC) intending to achieve adequately fitting models while
avoiding overfitting. The final main-effects logistic regression
model was further investigated for statistical interactions between
serogroups and adjustment variables using BIC. The variables
selected for the final logistic regression models, were then used in a
multivariable Poisson regression models with robust error variance
to obtain risk ratios and associated CIs.
Ethics statement
In Germany STEC and HUS notification data are collected
within the legal framework of the Infection Protection Act [37].
The national notification database which is hosted by the Robert
Koch Institute (RKI), Germany’s federal level public health
institute, is in essence a public use file (http://www3.rki.de/
SurvStat/). Approval by an ethics committee and written consent,
respectively, was not required because reporting data transmitted
to the national notification database are anonymous.
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Results
Study population
From 2004 through 2011, 12,587 STEC-illnesses were ascer-
tained in the German reporting system. Except for 2011 where
4,909 STEC cases and 648 STEC-associated HUS were reported,
annual reporting frequencies ranged from 834 to 1,180 STEC
cases, corresponding to an incidence of 1 and 1.4 per 100,000, and
from 32 to 60 cases of STEC-associated HUS (incidence ,0.1 per
100,000).
Of the 12,587 reported STEC-illnesses, 579 cases were
excluded from the analyses: 380 cases due to missing values in
covariates or outcome variable, and 199 cases with potentially
hospital-acquired infections (including 44 based on the imputation
procedure). After preliminary analysis, we decided to exclude all
cases with unknown O-antigen in 2011 (n = 3,608). The rational
for this decision was that most of these illnesses likely belonged to a
large outbreak of STEC O104:H4. Case-patients in 2011 with
unknown STEC serogroup differed markedly from those in
previous years. They were substantially older (median age 2011:
41 years vs. 2004–2010: 9 years), hospitalizations were twice as
common (2011: 51% vs. 2004–2010: 24%) and more women were
affected in 2011 (58%; 2004–2011: 51%). The majority of these
cases (n = 2,392) met the case definition of the STEC O104:H4
outbreak [34]. Thus, including them would have largely deter-
mined the estimates for the group of case-patients for which the
serogroup was not reported, thereby biasing the results.
Overall, 8,400 cases, incl. 627 (7%) HUS cases were analyzed.
Median age of cases from 2004 through 2010 was 8 years
(interquartile range [IQR], 2–43 years), and for 2011, 34 years
(IQR, 12–56 years). Slightly more reported cases were female
(53%), particularly in adults as of 20 years of age (62%).
For 4,325 cases (51%), 3,793 STEC and 532 HUS cases,
serotyping results were reported. Serotyping information was
significantly more frequently reported for HUS-cases (85%) than
for STEC gastroenteritis cases (49%, p-value of chi-squared test
,0.001). STEC belonged to 106 different serogroups (including
O-non-typable and O-rough) with O104 as most frequently
reported O-antigen (exclusively in 2011), followed by O157
(table 1). Except for 2011, serogroup distribution was fairly
constant over the years with O157 being the most frequently
reported serogroup, but accounting for less than 20% of the cases
with available serogroup information. Case-patients’ age varied
markedly among serogroups. Median age of cases infected by
STEC of serogroups O157, O26, O103, O111, and O145 was ,5
years, whereas that of O128, O104 and O91 was $18 years.
Among the 8,400 cases in this study, 2,454 (29%) hospitaliza-
tions were observed. The proportion of hospitalized cases varied
across STEC serogroups and ranged from 11% for O103 to 68%
for O104 (46% for O157) and across age-groups; it was lowest in
children ,3 years (21%) and highest in case-patients .65 years
(53%, table 2).
30 deaths (0.4%) with a (co-)causal contribution of an STEC
infection were ascertained in the surveillance system with a
patient’s median age of 60 years (IQR 2–82 years, table 3). The
advanced median age was largely driven by STEC O104 cases,
which accounted for the largest number of deaths (n = 11),
followed by STEC O157 (n = 9). These two serogroups had the
highest case-fatality ratio (1.2% each). Most cases for which death
was recorded (n = 21) had HUS (case fatality: 3.4% compared to
0.1% for STEC-gastroenteritis), e.g., all fatal cases of STEC O157
had HUS (n = 9). Nearly 1/4 of fatalities (n = 8) was found in
children ,3 years (all had HUS), but almost half (n = 14) occurred
in the highest age category (.65 years), of which most were
infected by STEC O104.
Risk analysis
Hospitalization. In univariable analysis, only cases infected
by O104 had a higher risk of hospitalization than those infected by
O157 (table 4). Hospitalization risks of patients infected with other
non-O157 serogroups were consistently and markedly lower. The
average hospitalization risk for a patient infected by a non-O157
STEC (except O104) was less than half that of STEC O157. A
multivariable model, adjusted for case-patients’ age and residence,
did not change the rank order among the serogroups and changed
risk ratio-estimates only slightly (table 4). Statistical interaction
terms of the different covariates did not improve the BIC of the
model. The risk of hospitalization for case-patients infected by
STEC O104 was 33% higher than that of STEC O157 (RR, 1.33;
CI, 1.19–1.45). The RR of the other non-O157 STEC ranged
from 0.54 for O145 to 0.27 for serogroup O103.
Mortality. Age-adjusted mortality risk (table 5) was highest
for patients infected by STEC O157 and O104 with no statistically
significant difference between them (RR, 0.89; CI, 0.32–2.49).
The risk for patients infected by any conventional non-O157
STEC was less than 10% compared with O157 (RR, 0.09; CI,
0.02–0.32). None of the other explanatory variables improved the
BIC of the model.
Discussion
We used nationwide reporting data from Germany to assess
differences among STEC serogroups with regard to virulence -
measured by hospitalization and death – irrespective of patients’
age. This study yielded three main findings: First, cases infected by
STEC O157, the most prominent STEC serogroup worldwide,
were markedly more likely to be hospitalized or die compared to
those infected by any of the non-O157 serogroups - except O104.
Second, the investigated non-O157 STEC serogroups (excluding
O104) varied in their virulence, although the difference across
those non-O157 serogoups was less pronounced than the
difference between single non-O157 serogroups and STEC
O157. Third, case-patients infected by STEC O104, all part of
one large outbreak in 2011, had a 1/3 higher risk of hospitaliza-
tion and a comparable risk of dying than those infected by O157,
according to German surveillance data.
These population-based data provide evidence for the excep-
tional virulence of O157 STEC, which accords with smaller
studies that found a higher proportion of cases with bloody
diarrhea or HUS in patients infected by STEC O157 than non-
O157 STEC [13,20,21,30,38]. The presence of a rare sorbitol-
fermenting clone of STEC O157:H- in Germany, which is
believed to be of heightened virulence and seldom found in other
countries yet, may have contributed to the observed difference in
virulence between O157 and non-O157 STEC. However,
sorbitol-fermenting STEC O157:H- is rarely diagnosed in patients
without HUS [39] and most STEC O157 isolated in Germany
from HUS patients in the study period belonged to sorbitol-
nonfermenting strains. Therefore the impact of this clone to the
overall virulence of serogroup O157 in this study likely is small.
Patients infected by a non-O157 STEC (excluding O104) had, on
average, less than half the risk to become hospitalized and 1/10
the risk of dying compared with O157-infected case-patients. The
lowest hospitalization risk, only 1/4 that of O157, was found for
patients infected by STEC O103, a serogroup frequently isolated
from STEC gastroenteritis patients in Germany. Differences in
hospitalization risks among the most frequently typed non-O157
Virulence of STEC Serogroups
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serogroups were smaller than their risk compared to O157.
Reported hospitalization is a fairly crude proxy for disease severity
and other considerations, e.g. precautionary aspects, may
contribute to the decision to hospitalize a patient. Therefore,
collecting more detailed clinical markers of disease severity, e.g.,
duration of illness, severity (e.g., visible blood in stool) and
frequency of loose stools may permit a more accurate character-
ization of disease severity, and thereby to better differentiate
between the virulence of non-O157 serogroups.
Patients infected by STEC O104 belonged to the largest ever
documented HUS outbreak that occurred in 2011. The causative
agent, an E. coli O104:H4, combined virulence traits of STEC and
of enteroaggregative E. coli [34,40,41]. A comparatively high
virulence has been attributed to this strain based on the high
proportion of HUS ascertained in this outbreak [34,42]. This
proportion could be corroborated in two additional studies that
observed closed groups of people, i.e., in studies without the risk of
disproportionately ascertaining severe cases. Yet, cases infected by
STEC O104, unprecedentedly even HUS cases, were mostly
adults, predominantly women. Furthermore, clinical courses of
pediatric O104 HUS-patients did not differ from those infected by
other STEC [43]. Host factors may have also contributed, at least
partially, for the severity of this outbreak [44]. Of note, our
comparison accounts for the most important (proxies for) host
characteristics, age and sex, and revealed that the virulence of
STEC O104(:H4) is comparable with that of STEC O157. We
caution, however, for over-interpreting these data. Hospitalization
risk was influenced by the heightened awareness and anxiety of
Table 1. Characteristics of STEC-illnesses reported in Germany 2004-2001 –stratified by STEC serogroup.
Male sex Age* Hospitalizations Fatalities HUS
Serogroup
No. of
patients No. of patients (%) Median (IQR) No. of patients (%) No. of patients (%) No. of patients (%)
O157 721 338 (46.9) 3 (1–10) 333 (46.2) 9 (1.2) 189 (26.2)
O104 917 336 (36.6) 44 (29–62) 623 (67.9) 11 (1.2) 264 (28.8)
O26 514 278 (54.1) 1.5 (1–4) 94 (18.3) 1 (0.2) 31 (6.0)
O103 426 215 (50.5) 2 (1–6) 48 (11.3) 0 (0.0) 3 (0.7)
O91 323 132 (40.9) 23 (6–48) 61 (18.9) 0 (0.0) 1 (0.3)
O145 190 84 (44.2) 2 (1–7) 45 (23.7) 1 (0.5) 15 (7.9)
O128 106 49 (46.2) 18 (2–40) 25 (23.6) 0 (0.0) 1 (0.9)
O111 100 51 (51.0) 2 (1–4) 21 (21.0) 0 (0.0) 10 (10.0)
Other 1,028 474 (46.1) 8 (1–39) 214 (20.8) 1 (0.1) 18 (1.8)
Unknown 4,075 1,994 (48.9) 9 (2–45) 990 (24.3) 7 (0.2) 95 (2.3)
Total 8,400 3,951 (47.0) 8 (2–43) 2,454 (29.2) 30 (0.4) 627 (7.5)
Percentages are calculated within serogroup categories;
*in years.
Abbrevations: IQR – interquartile range.
doi:10.1371/journal.pone.0078180.t001
Table 2. Number of STEC-illnesses reported in Germany 2004–2011 and percentage of hospitalized case-patients – by age-group
and serogroup.
Age group (years)
,3 3–9 10–18 19–40 41–65 .65
Serogroup No. % hosp No. % hosp No. % hosp No. % hosp No. % hosp No. % hosp
O157 303 41.9 222 49.5 52 65.4 48 29.2 53 39.6 43 62.8
O104 8 50.0 23 78.3 68 70.6 300 66.0 327 63.9 191 76.4
O26 344 16.6 91 17.6 12 41.7 21 14.3 33 18.2 13 53.8
O103 243 8.6 89 9.0 18 11.1 29 13.8 28 28.6 19 26.3
O91 45 8.9 62 17.7 42 28.6 72 12.5 61 14.8 41 39.0
O145 108 21.3 43 16.3 12 58.3 10 20.0 10 20.0 7 57.1
O128 33 27.3 11 27.3 10 40.0 27 18.5 15 6.7 10 30.0
O111 68 17.6 16 31.3 5 20.0 3 33.3 5 20.0 3 33.3
Other 360 20.0 173 17.3 67 11.9 184 13.0 142 24.6 102 44.1
Unknown 1,314 19.9 771 19.6 269 29.7 579 17.1 634 24.1 508 48.2
Total 2,826 20.9 1,501 23.9 555 36.2 1,273 28.2 1,308 34.0 937 53.3
Percentages are calculated within serogroup categories.
doi:10.1371/journal.pone.0078180.t002
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gastroenteritis patients during the outbreak period, which likely led
to a more liberal hospitalization policy of physicians in primary
care and in hospitals.
Our study is subject to potential biases and limitations. We used
national surveillance data, i.e., STEC-illnesses that were reported
to local health departments (and transmitted to RKI via health
authorities at federal state level). Ascertainment of patients’
hospitalization status or death is likely incomplete, particularly if
death occurred after local health departments finished their case
investigation. Furthermore, reported illnesses may not be repre-
sentative for all cases occurring in the German population.
Nonetheless, our comparisons should still be valid under the
proviso that serotyping was conducted independent from the
decision to hospitalize the patient or from its death. Serotyping
results were available for only 51.5% of all reported cases. This
proportion was not substantially higher in hospitalized cases (and
deceased cases), indicating that strain serotyping was not initiated
more frequently in cases with severe outcomes – with one
exception: Typing information for STEC isolated from gastroen-
teritis cases (without HUS) was less complete than for those from
HUS patients. Consequently, investigated serogroups dispropor-
tionately contained more severe, i.e., HUS-associated, cases and
STEC O157 was the serogroup most frequently found in STEC
from HUS patients (except O104). As a result, the magnitude of
the difference found between O157 and conventional non-157
serogroups with regard to hospitalization and death may have
been overestimated by this study. However, as HUS cases
represented only 7% of the study cases, the extent of this bias
appears to be limited. Parenthetically, the disproportionate lack of
typing information in STEC gastroenteritis cases should be
considered when interpreting the ability of serogroups to cause
HUS; likely the proportion of HUS cases among serogroup-
specific illnesses are overestimated (except for O104).
The serogroup antigens, lipopolysaccharides on the bacterial
surface, serve as a proxy for the genomic content of the strain.
When coupled with information on virulence genes, particularly
Shiga toxin genotype (stx), a more accurate assessment of the
strains virulence can be achieved. Indeed, even among STEC
O157 there are differences in the potential to cause HUS,
depending on the strains’ stx profile [21,45]. Particularly stx2 is
associated with severe disease [46,47], but differences exist among
subtypes of stx2 [45,48]. Thus, a diagnostic procedure that detects
in one diagnostic step the relevant stx-subtypes together with the
eae-gene (and, ideally, the most important HUS serogroups) would
allow a quick assessment of the strains’ likely potential to cause
HUS. Unfortunately, current diagnosis in primary care laborato-
ries does not provide such information. Time is of the essence in
the management of patients with acute bloody diarrhea (of all
ages) [49], a symptom frequently caused by virulent STEC strains.
Early intravenous volume expansion during diarrhea is associated
with relative nephroprotection during subsequent pediatric HUS
[50]. Furthermore, risk of secondary STEC O157 transmission is
considerable, occurs early in the course of illness and can be
markedly reduced by prompt spatial isolation of vulnerable
contacts or of the primary patient [51].
Fortunately, presumptive identification of sorbitol-nonferment-
ing STEC O157 can be achieved within 24 hours after specimen
Table 3. Deaths among reported STEC-illnesses in Germany
2004–2011 - by serogroup.
Fatalities Age* Underlying HUS
Serogroup** No. of patients Median (IQR) No. of patients (%)
O157 9 4 (1–6) 9 (100)
O104 11 80 (62–87) 7 (64)
O26 1 0 0 (0)
O145 1 73 0 (0)
Other*** 1 79 0 (0)
Unknown 7 7 (0–82) 5 (71)
Total 30 60 (2–82) 21 (70)
Percentages are calculated within serogroup categories,
*in years.
**no fatalities were reported for infections with STEC O91, O103, O111, and
O128.
***serogroup of the fatal case in this category was reported as Ont (non-typable
O antigen).
Abbrevations: HUS – hemolytic-uremic syndrome, IQR – interquartile range.
doi:10.1371/journal.pone.0078180.t003
Table 4. Serogroup specific risk ratios for hospitalization
among STEC-illnesses reported in Germany 2004–2011.
Univariable model Multivariable model*
Serogroup RR (95% CI) RR (95% CI)
O157 Reference Reference
O104 1.47 (1.34–1.61) 1.33 (1.19–1.45)
O145 0.51 (0.39–0.67) 0.54 (0.41–0.70)
O128 0.51 (0.36–0.73) 0.49 (0.35–0.69)
Unknown 0.53 (0.48–0.58) 0.48 (0.44–0.53)
O111 0.45 (0.31–0.67) 0.48 (0.33–0.71)
Other 0.45 (0.39–0.52) 0.44 (0.38–0.51)
O26 0.40 (0.32–0.48) 0.43 (0.35–0.52)
O91 0.41 (0.32–0.52) 0.38 (0.30–0.48)
O103 0.24 (0.18–0.32) 0.27 (0.20–0.35)
Non-O157/O104** 0.41 (0.37–0.46)***
Risk ratios were calculated using Poisson regression with robust error estimate.
*adjusted for age and region of cases’ residence.
**all except serogroups O157 and O104.
***calculated in a separate model (serogroup categories: O157, non-O157/
O104, O104, unknown).
Abbrevations: RR –risk ratio, CI – confidence interval.
doi:10.1371/journal.pone.0078180.t004
Table 5. Serogroup specific risk ratios for mortality among
STEC-illnesses reported in Germany 2004–2011.
Univariable model Multivariable model*
Serogroup RR (95% CI) RR (95% CI)
O157 Reference Reference
O104 0.96 (0.40–2.31) 0.89 (0.32–2.49)
Unknown 0.14 (0.05–0.37) 0.13 (0.05–0.35)
Non-O157/O104** 0.09 (0.02–0.33) 0.09 (0.02–0.32)
Risk ratios were calculated using Poisson regression with robust error estimate.
*adjusted for age.
**all except serogroups O157 and O104.
Abbrevations: RR – risk ratio, CI – confidence interval.
doi:10.1371/journal.pone.0078180.t005
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receipt [50]. Thus, as long as primary care diagnostics do not
provide the relevant information on the strains’ virulence profile,
we recommend using selective and differential media for STEC
O157 diagnosis (coupled with nonculture STEC assays for
detecting non-O157 STEC [19]) for stools submitted from persons
with acute community-acquired diarrhea to enable timely
identification of the most important subgroup of HUS-associated
E. coli – sorbitol-nonfermenting STEC O157.
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